What is Trifluridine and Tipiracil combination medicine
Trifluridine and tipiracil is a combination product that is FDA approved for the treatment of metastatic colorectal cancer and metastatic gastric or gastroesophageal junction cancer after progression on several previous lines of therapy.
Trifluridine was initially developed in the 1960s but was abandoned due to a lack of objective responses and very short half-life (12 minutes) when administered by intravenous injection.
Trifluridine is rapidly inactivated by thymidine phosphorylase after administration; tipiracil inhibits thymidine phosphorylase, preventing this rapid degradation and increasing trifluridine exposure.
Trifluridine; tipiracil can cause severe myelosuppression. Monitor complete blood counts as an interruption of therapy or dose reduction may be necessary.
Brand Name
Lonsurf
Indications
- colorectal cancer
- gastric cancer
For the treatment of metastatic colorectal cancer in patients who have previously been treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF biologic therapy, and if RAS wild-type, an anti-EGFR therapy
Side Effects
- abdominal pain
- alopecia
- anemia
- anorexia
- asthenia
- bone marrow suppression
- diarrhea
- dysgeusia
- fatigue
- fever
- infection
- nausea
- neutropenia
- pneumonitis
- pulmonary embolism
- QT prolongation
- stomatitis
- thrombocytopenia
- vomiting
Monitoring Parameters
- CBC with differential
- pregnancy testing
Contraindications
- anemia
- bone marrow suppression
- breast-feeding
- chemotherapy
- children
- contraception requirements
- fever
- geriatric
- infants
- infection
- male-mediated teratogenicity
- neutropenia
- pregnancy
- pregnancy testing
- radiation therapy
- reproductive risk
- thrombocytopenia
Interactions
- Palifermin
- Penicillamine
- Tuberculin Purified Protein Derivative, PPD
